



## (51) International Patent Classification:

*C07K 14/33* (2006.01)      *C12N 15/70* (2006.01)  
*C12P 21/02* (2006.01)      *C12N 15/866* (2006.01)  
*C12N 15/62* (2006.01)      *C12P 21/06* (2006.01)  
*C12N 9/50* (2006.01)

## (21) International Application Number:

PCT/US2011/022272

## (22) International Filing Date:

24 January 2011 (24.01.2011)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/286,963      25 January 2010 (25.01.2010)      US

(71) Applicant (for all designated States except US): **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, California 92612 (US).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **GHANSHANI, Sanjiv** [US/US]; 11 Morningside, Irvine, California 92603 (US). **LE, Linh Q.** [US/US]; 12955 Crawford Drive, Tustin, California 92782 (US). **LIU, Yi** [US/US]; 29 Vassar Aisle, Irvine, California 92612 (US). **STEWART, Lance E.** [US/US]; 35 Sweet Rain, Irvine, California 92614 (US).

(74) Agents: **ABEL, Kenton B.** et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, California 92612 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

## Published:

- with international search report (Art. 21(3))

[Continued on next page]

(54) Title: METHODS OF INTRACELLULAR CONVERSION OF SINGLE-CHAIN PROTEINS INTO THEIR DI-CHAIN FORM




FIG. 1.

(57) Abstract: The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.



- 
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))* — *with sequence listing part of description (Rule 5.2(a))*